Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics announced one oral and two poster presentations at ACR Convergence 2026 (November 6-11, Orlando) featuring updated clinical data for AlloNK (AB-101) plus rituximab in autoimmune diseases. The oral presentation covers at least 20 refractory RA patients, 11 Sjögren disease patients and at least 5 systemic sclerosis patients from the Phase 2a basket trial with at least six months of follow-up, with posters citing deep B-cell depletion comparable to CD19 CAR T and a favorable safety profile across a 60-patient cohort.
Key figures
- Drug Name
- AlloNK (AB-101)
- Phase Of Trial
- Phase 2a basket trial; Phase 3 registrational trial initiating 2H 2026
- Patients sjogren
- 11
- Patients systemic sclerosis
- at least 5
- Total patients safety cohort
- 60
- Patients ra with 6mo followup
- at least 20
- Phase3 eligible ra patients in webcast
- at least 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.